NEO241220P29000
- 0.00
- 0.000.00%
NeoGenomics Newsroom
NeoGenomics Is Maintained at Neutral by B of A Securities
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $19
NeoGenomics Study Highlights CtDNA's Potential To Predict Recurrence In High-Risk Melanoma; RaDaR Sequencing Assay Identifies Molecular Residual Disease Across Broader Patient Range, Enabling Earlier Detection And Prognosis Monitoring
NeoGenomics' Newly Published Study Underscores Potential of CtDNA as a Predictive Tool for Monitoring Patients With High-Risk Melanoma
Strong Week for NeoGenomics (NASDAQ:NEO) Shareholders Doesn't Alleviate Pain of Three-year Loss
NeoGenomics Analyst Ratings
Jefferies Initiates NeoGenomics at Buy With $22 Price Target
Jefferies Initiates NeoGenomics(NEO.US) With Buy Rating, Announces Target Price $22
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research
NeoGenomics To Present Four Studies At AMP 2024 Showcasing CtDNA And NGS Advancements For Cancer Diagnostics And Personalized Treatment
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of CtDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Felicia Williams Joins NeoGenomics Board of Directors
Express News | Felicia Williams Joins Neogenomics Board of Directors
Earnings Scheduled For November 14, 2024
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $18 to $21
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $18 to $20
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)